July 16, 2012 Comments Off on GlaxoSmithKline wins takeover bid for Human Genome
U.K. drug maker GlaxoSmithKline has secured its takeover of longtime partner Human Genome Sciences after agreeing to pay more, a move to expand GSK’s drug portfolio in crucial areas: biologic drugs and treatments for the hundreds of millions of people ...
Tagged with: benlysta biotech diabetes glaxosmithkline human genome sciences lupus poison pill rockville takeover
Read More »July 15, 2012 Comments Off on Report: GSK in deal talks with Human Genome
NEW YORK — GlaxoSmithKline PLC is reportedly talking this weekend with Human Genome Sciences Inc. about its $2.6 billion offer for the Rockville-based biotech company. British drug maker GlaxoSmithKline made its first bid for the biotech company in April and ...
Tagged with: benlysta bid biotech GlaxoSmithKline PLC Human Genome Sciences Inc. joe biden lupus takeover
Read More »May 17, 2012 Comments Off on Human Genome adopts ‘poison pill’ measure
ROCKVILLE — Biotech drugmaker Human Genome Sciences Inc.’s board has adopted a “poison pill” shareholder rights plan to ward off unsolicited takeover bids, and it also has rejected a buyout offer worth nearly $2.6 billion from British pharmaceutical giant GlaxoSmithKline ...
Tagged with: benlysta biotech GlaxoSmithKline PLC human genome sciences lupus poison pill shares stock
Read More »May 9, 2012 Comments Off on GlaxoSmithKline in takeover bid for Human Genome
LONDON — GlaxoSmithKline PLC has made an offer to take over Rockville-based drug maker Human Genome Sciences Inc. which values the company at nearly $2.6 billion. GlaxoSmithKline, which has profit-sharing agreements with HGS on three drugs but a minimal shareholding, ...
Tagged with: benlysta drugs GlaxoSmithKline PLC human genome sciences lupus Nasdaq price shareholder takeover
Read More »April 19, 2012 Comments Off on Human Genome rejects GlaxoSmithKline’s $2.59B bid
The decision by Rockville-based biotech drugmaker Human Genome Sciences Inc. to reject an unsolicited $2.59 billion takeover bid Thursday may increase the eventual sale price of the company, analysts said. The question is by how much. “For the most part, ...
Tagged with: benlysta biotech diabetes drugs glaxosmithkline human genome sciences lupus selling shares
Read More »July 14, 2011 Comments Off on Rockville-based Human Genome Sciences gets approval for new lupus drug
Benlysta, a drug to treat lupus, has received approval from European regulators to be marketed in Europe, the drug’s co-makers, Human Genome Sciences Inc. of Rockville, and GlaxoSmithKline, its London-based parent, announced. The European approval came two days after Benlysta, ...
Tagged with: approval drug europe FDA glaxosmithkline lupus maryland rockville treatment u.s. food and drug administration
Read More »March 9, 2011 Comments Off on Human Genome’s lupus drug wins approval
WASHINGTON — The Food and Drug Administration on Wednesday approved the first new drug to treat lupus in over 50 years, a milestone that medical experts say could prompt development of other drugs that are even more effective in treating ...
Tagged with: approval drug FDA food and drug administration GlaxoSmithKline PLC lupus maryland rockville
Read More »November 12, 2010 Comments Off on FDA scrutinizes benefit of long-awaited lupus drug
WASHINGTON — Federal health officials said Friday that the first new drug developed to treat lupus in decades relieves disease symptoms, but they questioned the significance of its benefits, which varied across difference patient groups. Human Genome Sciences is asking ...
Tagged with: FDA federal government food and drug administration human genome sciences lupus medical Stocks
Read More »
Maryland Daily Record Maryland's trusted source for business and legal news